1. GBS with autonomic dysfunction (labile BP, vasodilation causing low DBP)
2. Infectious/sepsis-related causes (fever driving vasodilation, low DBP = wide pulse pressure = sepsis physiology)
3. Specific toxins (tetrodotoxin, organophosphates with autonomic features)
4. Beriberi (wet beriberi: neuropathy + vasodilatory low DBP heart failure)

Ascending Paralysis + Low DBP + Fever: Clinical Approach

Understanding the Triad

• Autonomic nervous system dysregulation (GBS pandysautonomia)
• Sepsis/systemic infection causing vasodilatory shock
• High-output cardiac states (wet beriberi)
• Direct toxin-mediated vasodilation

Step 1: Differentiate Ascending vs. Descending Paralysis

Step 2: Differential Diagnosis (Fever Modifies the List)

A. INFECTIOUS CAUSES (Fever Prominent)

1. Poliomyelitis / Poliovirus-like Illness (Enteroviral Myelitis)

• Fever + flaccid asymmetric paralysis (anterior horn cell destruction)
• Meningeal signs + CSF pleocytosis (vs. GBS which has albuminocytological dissociation)
• Low DBP from sepsis physiology
• Key: asymmetric, predominantly motor, early fever
• Other enteroviruses (EV-D68, EV-A71, West Nile virus) cause similar "acute flaccid myelitis (AFM)"

2. West Nile Virus / Acute Flaccid Myelitis

• Fever + headache + asymmetric flaccid paralysis (anterior horn cell involvement)
• Often with encephalitis or meningitis
• Diagnosis: serology (CSF IgM), PCR
• Low DBP from systemic febrile illness / encephalitis-related autonomic dysregulation

3. Rabies (Paralytic Form, ~20%)

• Paralytic rabies: ascending flaccid paralysis progressing to quadriparesis, facial paralysis - closely mimics GBS
• Fever + autonomic dysfunction (labile BP, low DBP)
• History of animal bite critical; CSF may show mild pleocytosis
• As per Harrison's 22E: "Flaccid paralysis in limb(s) progressing to quadriparesis with facial paralysis" - [Harrison's Principles of Internal Medicine 22E, p. 5293]

4. Diphtheria

• Exotoxin-mediated neuropathy - descending initially (palatal palsy, accommodation palsy) then can generalize
• Fever + characteristic pseudomembrane
• Can cause autonomic dysfunction with low BP

5. Neuroborreliosis (Lyme Disease)

• Ascending weakness + radicular pain + fever
• Facial palsy (Bannwarth syndrome)
• Endemic exposure history

B. GBS WITH AUTONOMIC DYSFUNCTION + FEVER (Septic Trigger)

• Labile blood pressure (wide swings between hypertension and hypotension)
• Tachycardia / bradycardia
• Low DBP from parasympathetic over-activation or sympathetic dysregulation
• Urinary retention, ileus, excessive sweating

"In Guillain-Barré syndrome, up to two thirds of patients may have autonomic dysfunction, which can be life-threatening. Manifestations include labile blood pressure and heart rate, paralytic ileus, and urinary retention." - [Goldman-Cecil Medicine, p. 4063]

• Required: Progressive bilateral limb weakness + areflexia/hyporeflexia
• Supportive: Progression over days to 4 weeks, relative symmetry, bifacial palsies, autonomic dysfunction, mild sensory signs, elevated CSF protein with <10 cells/μL
• [Bradley and Daroff's Neurology in Clinical Practice, p. 2663]

• AIDP (commonest in West)
• AMAN / AMSAN (axonal, associated with C. jejuni - more severe)
• Miller Fisher syndrome (ophthalmoplegia + ataxia + areflexia)
• Pandysautonomia variant

C. TOXIC / METABOLIC CAUSES (Fever from Secondary Infection)

Beriberi (Wet Beriberi - Thiamine Deficiency)

• Classic triad: ascending sensorimotor neuropathy + high-output heart failure + low DBP (vasodilatory)
• Wide pulse pressure is characteristic: low DBP with preserved or elevated systolic BP
• Fever from secondary infection
• Malnutrition, alcoholism, rice-based diet
• This is the one condition where low DBP is PATHOPHYSIOLOGICALLY central (vasodilation from thiamine-deficient peripheral vasodilation + cardiac failure)
• Treatment: IV thiamine immediately

Organophosphate / Carbamate Poisoning

• Intermediate syndrome: ascending paralysis 24-96 hours post-acute cholinergic crisis
• Autonomic dysfunction with wide BP variability
• Fever from aspiration or excess secretions
• Toxidrome: miosis, bradycardia, excessive secretions; but intermediate syndrome may have a "cleaner" presentation

Marine Toxins

• Tetrodotoxin (puffer fish): ascending paralysis within 4-24 hours, hypotension, bradycardia
• Saxitoxin (paralytic shellfish poisoning): similar
• Ciguatoxin: paresthesias, weakness, autonomic dysfunction
• Fever may be low-grade from systemic effect

Heavy Metal Toxicity

• Arsenic: ascending neuropathy + Mees' lines, GI illness, low BP
• Thallium: ascending neuropathy + alopecia

Step 3: Key Differentiating Features

Step 4: Immediate Investigations

Bedside / Emergency

• Vital signs: BP (both lying and standing - check for orthostatic component), HR, SpO2
• Bedside spirometry: Forced Vital Capacity (FVC) - if <20 mL/kg, observe in ICU; <15 mL/kg consider intubation (the "20-15-30 rule" in GBS: FVC <20, MIP < -30 cmH2O)
• ECG: Autonomic instability causes cardiac arrhythmias in GBS
• Serum potassium: Hypokalemic periodic paralysis (low K+ = ascending paralysis + low DBP from associated conditions)
• Blood glucose, rapid sepsis screen

Laboratory

• CBC, CRP, procalcitonin (infection)
• Serum electrolytes (K+, Mg2+, Na+, Ca2+)
• LFTs, RFTs
• Thiamine levels (if wet beriberi suspected)
• Blood cultures (if febrile)
• Serology: anti-ganglioside antibodies (GM1, GD1b, GQ1b), C. jejuni serology
• Organophosphate screen (RBC cholinesterase)

CSF Analysis (Lumbar Puncture)

Nerve Conduction Studies / EMG

• Confirms demyelination (GBS/AIDP): slow conduction velocity, conduction blocks, prolonged F-waves
• Axonal pattern (AMAN/AMSAN): reduced amplitudes, inexcitable nerves
• Normal in early GBS (can lag 1-2 weeks)

Imaging

• MRI spine: Rule out compressive myelopathy, transverse myelitis (T2 signal changes), epidural abscess
• MRI brain: Encephalitis, brainstem involvement (West Nile, rabies, ADEM)
• Chest X-ray: Aspiration, mediastinal widening (diphtheria - anthrax in bioterrorism)

Step 5: Management Approach

1. Airway - PRIORITY ONE

• Monitor FVC every 4-6 hours in any progressive ascending paralysis
• The "20-15-30 rule":
  • FVC < 20 mL/kg → ICU admission
  • FVC < 15 mL/kg → consider intubation
  • MIP < -30 cmH2O → consider intubation
  • Bulbar weakness → early intubation regardless of FVC
• Hypercarbia is a late and unreliable sign - do not wait for it

2. Hemodynamic Management (Low DBP)

• Avoid aggressive antihypertensives (labile BP in GBS - hypertension follows hypotension)
• For symptomatic hypotension: IV fluids cautiously, avoid vasoconstrictors unless refractory
• If wide pulse pressure + warm extremities + fever → think sepsis or beriberi (vasodilatory)
• IV thiamine 200-500 mg immediately if wet beriberi suspected (safe, therapeutic and diagnostic)

3. Treat the Underlying Cause

4. GBS-Specific ICU Management

• IVIG or plasmapheresis (no benefit to combining both)
• Cardiac monitoring (autonomic instability causes arrhythmias, sudden death)
• DVT prophylaxis (immobile patients)
• Nasogastric feeding if bulbar palsy
• Pain management (neuropathic pain with gabapentin, carbamazepine)
• Physiotherapy early

Step 6: Red Flags Requiring Immediate Action

• Rapid respiratory failure (FVC declining fast) → intubate, ICU
• Cardiac arrhythmia (autonomic GBS) → continuous cardiac monitoring, treat cause
• Bulbar palsy (dysphagia, dysarthria) → aspiration risk, early intubation
• Hypotension unresponsive to fluids → consider sepsis, beriberi, adrenal crisis
• Fever + pleocytosis on LP → treat empirically for bacterial meningitis/encephalitis while awaiting cultures
• Animal bite history → rabies post-exposure prophylaxis/isolation

Clinical Summary Algorithm

Ascending Paralysis + Fever + Low DBP
            ↓
1. Secure Airway (FVC monitoring) - FIRST
            ↓
2. Is paralysis TRULY ascending (legs first)?
   ├── Yes → GBS, polio, AFM, tick, beriberi, toxins
   └── No (cranial nerves first) → Botulism, diphtheria (descending)
            ↓
3. Fever CHARACTER:
   ├── High fever + asymmetric + CSF pleocytosis → Polio/AFM/West Nile/Rabies
   ├── Low-grade + symmetric + areflexia + albuminocytological dissociation → GBS (infection trigger)
   └── Fever + wide pulse pressure + heart failure signs → Wet beriberi (give thiamine NOW)
            ↓
4. Low DBP TYPE:
   ├── Vasodilatory (warm, bounding pulse, wide PP) → Sepsis, beriberi, GBS autonomic
   └── Cardiogenic (cold, narrow PP) → Diphtheritic myocarditis, stress cardiomyopathy (GBS)
            ↓
5. KEY EXAM:
   ├── Find tick → REMOVE immediately
   ├── Pupil dilation → Botulism
   ├── Pseudomembrane throat → Diphtheria antitoxin
   └── Animal bite → Rabies protocol

• [Bradley and Daroff's Neurology in Clinical Practice, block28, p. 2663] - GBS diagnostic criteria and differential diagnosis
• [Adams and Victor's Principles of Neurology, 12th Ed, block15, p. 2070-2073] - GBS differential vs. polio, West Nile, tick paralysis
• [Miller's Anesthesia 10e, block33, p. 12034-12035] - GBS critical care, respiratory failure criteria, autonomic dysfunction
• [Goldman-Cecil Medicine, block56, p. 4063] - GBS autonomic dysfunction, labile BP
• [Tintinalli's Emergency Medicine, block15] - Poliomyelitis clinical features; clinical features of acute paralysis
• [Merck Manual Professional - GBS] - Differential: myasthenia, botulism, polio, tick, West Nile
• [Neurology.org clinical case] - Wet beriberi as ascending neuropathy with low DBP/heart failure

Minoxidil for Androgenetic Alopecia (AGA): Complete Clinical Guide

Background & Mechanism

• Opening of ATP-sensitive potassium channels in follicular cells
• Increases follicle size, resulting in thicker hair shafts
• Stimulates and prolongs the anagen (growth) phase of the hair cycle
• Increases the percentage of anagen follicles
• Increased proliferation of dermal papilla cells; decreased apoptosis in the germinative pool

Grading of AGA (Before Starting Treatment)

• Vertex balding responds better to minoxidil than frontal/hairline recession
• Norwood I-III: best candidates; IV-VII: limited benefit, may need surgical options

• Diffuse thinning over the crown with preserved frontal hairline
• Ludwig I: mild widening of part; II: moderate; III: extensive thinning

Formulations, Doses, and Approved Use

• Women: 0.625-2.5 mg/day (start low, e.g. 0.625 mg)
• Men: 0.625-5 mg/day (typically 2.5-5 mg)
• Also used for alopecia areata and chronic telogen effluvium in patients intolerant or unresponsive to topical form

Course of Treatment - Timeline

"Vertex balding is more responsive to therapy than frontal balding. Chronic dosing studies have demonstrated that the effect of minoxidil is not permanent, and cessation of treatment will lead to hair loss in 4-6 months." - [Katzung's Basic and Clinical Pharmacology, 16th Ed, p.1690]

"Minoxidil-induced hair growth is commonly associated with shedding of telogen hairs and a paradoxical worsening of hair loss ~3 to 6 weeks following initiation of treatment. However, this resolves with continued treatment." - [Dermatology 2-Volume Set 5e, Ch.69]

Side Effects

Topical Minoxidil

Oral Minoxidil (Low-Dose, Off-Label)

"Side effects of minoxidil include unwanted hypertrichosis of the cheeks or forehead, headache, ankle edema, and for topical preparations, allergic or irritant contact dermatitis... reported cardiovascular side effects from oral minoxidil (uncommon with low doses) include hypotension, tachycardia, and pericarditis." - [Dermatology 2-Volume Set 5e, Ch.157]

"The most common side effect with oral low-dose minoxidil is hypertrichosis. Additional potential side effects include postural hypotension, lower extremity edema, tachycardia, and headache." - [Goodman & Gilman's Pharmacological Basis of Therapeutics]

Withdrawal / Discontinuation

What Happens When You Stop

1. Weeks 2-6 post-stop: Shedding begins as hairs supported by minoxidil enter the telogen phase simultaneously (synchronized effluvium)
2. Months 3-6 post-stop: Visible thinning becomes apparent; shedding continues
3. Months 6-12 post-stop: Hair density returns to pre-treatment baseline (or where it would have been with natural disease progression)

"Hair growth was lost when [minoxidil] was discontinued." - [Goodman & Gilman's]

"Treatment must be continued or any drug-induced hair growth will be lost." - [Katzung 16th Ed]

Key Points on Withdrawal

• There is no "rebound" worse than baseline - hair returns to where genetics would have taken it, plus any progression during treatment
• Severity of post-discontinuation shed varies by duration of use, age, and severity of underlying AGA
• Tapering (gradually reducing dose/frequency over 3-6 months) may reduce the severity of the shed, though no robust RCT data supports this
• Combining with finasteride or DHT blockers before stopping can help maintain some of the benefit

Practical Prescribing Guide

Application (Topical)

• Apply 1 mL (solution) or half-cap (foam) to dry scalp twice daily
• Targeted application to the affected area (vertex, mid-scalp)
• Wash hands thoroughly after application
• Avoid contact with eyes and non-scalp skin
• Allow to dry before going to bed (to prevent transfer to pillow/face)

Monitoring

• Cardiovascular monitoring in patients with cardiac disease (due to possible hypotension)
• Check for contact dermatitis after 2-4 weeks
• Reassess at 6 months; if no improvement at 12 months, discontinue or reassess

Pregnancy & Breastfeeding

• Contraindicated - fetal hypertrichosis reported; topical systemic absorption unlikely but risk not established

Comparison with Other AGA Treatments

"Patients are advised to allow at least 6 months before expecting to see a therapeutic effect. If they discontinue... the AGA will return to its pre-treatment appearance." - [Dermatology 2-Volume Set 5e, re: finasteride, same principle applies to minoxidil]

Summary for Patient Counselling

1. Start: Expect initial shedding (weeks 3-6) - this is normal, continue treatment
2. Wait: First visible benefit at 4-6 months; full assessment at 12 months
3. Commit: Indefinite use required; stopping = reversal of benefit within 6-12 months
4. Form matters: 5% foam preferred if scalp irritation occurs (no propylene glycol)
5. Oral option: Useful if topical is inadequate or poorly tolerated; monitor for hypertrichosis, BP, edema
6. Pregnancy: Stop before conception; breastfeeding contraindicated
7. Combine: Finasteride + minoxidil provides complementary (additive) mechanisms in men

• Cummings Otolaryngology Head and Neck Surgery, Ch. 22 - Medical Treatment of AGA
• Katzung's Basic and Clinical Pharmacology, 16th Ed, p.1690 - Minoxidil pharmacology
• Goodman & Gilman's Pharmacological Basis of Therapeutics - Androgenic Alopecia
• Dermatology 2-Volume Set 5e (Bolognia), Ch.69 (AGA) and Ch.157 (side effects)
• Frontiers in Pharmacology 2025 - Topical, oral, sublingual minoxidil review
• PubMed: PMID 37665358 - Minoxidil + microneedling meta-analysis (2023); PMID 40056230 - Combined microneedling vs topical minoxidil meta-analysis (2025)